Over the last couple of years, the Triple-I Initiative has established itself as a showcase that's worth keeping an eye on.

The Texas Longhorns are no strangers to making or rewriting history, as the Longhorns softball program rewrites another chapter of its history on Friday night. The Longhorns headed into a two-game ...

In Moalboal (top right), visitors experience a different thrill with the sardine run off Panagsama Beach TAGBILARAN CITY. Bohol— The Cebu provincial government has turned over the implementation of ...

CHICAGO (WLS) -- Cook County it will continue funding the medical debt forgiveness program next year, once funds run out, Board of Commissioners President Tony Preckwinkle announced Tuesday. The ...

Luke Lindberg, USDA's undersecretary for trade and foreign agricultural affairs. (USDA photo) Luke Lindberg, USDA’s undersecretary for trade and foreign agricultural affairs, is the leading contender ...

When students talk about the ability to take Running Start courses during the summer, they don’t talk about credits; they talk about opportunity. For one high school student, enrolling in a summer ...

Without a doubt, one of the hottest new startup accelerators in tech right now is Andreessen Horowitz’s Speedrun program. Launched in 2023, the accelerator has an acceptance rate of less than 1%. In a ...

Social Security, which provides benefits to about 70 million Americans, could run out of money sooner than expected, according to a new report from the Congressional Budget Office. The Old-Age and ...

TURKU, Finland, Feb. 10, 2026 /PRNewswire/ -- Vaadin, the leading provider of Java web application frameworks, today announced the general availability of Swing Modernization Toolkit, a solution that ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.